BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status
NCT00779064
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
36
Enrollment
INDUSTRY
Sponsor class
Conditions
Atrial Fibrillation
Interventions
DRUG:
Rivaroxaban (BAY59-7939)
DRUG:
Rivaroxaban (BAY59-7939)
Sponsor
Bayer